Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 191-200 , August 2007

Hypersensitivity Reactions to Biological Drugs

  • Barbara Holmes Gobel

      Affiliations

    • Corresponding Author InformationAddress correspondence to Barbara Holmes Gobel, RN, MS, AOCN©, Northwestern Memorial Hospital, 251 E. Huron-Feinberg Pavilion 4-508, Chicago, IL 60611

References 

  1. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781–1790
  2. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA. 1997;278:1895–1906
  3. Weiss RB. Miscellaneous toxicities. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology. Ed 6. Philadelphia, PA: Lippincott Williams and Wilkins; 2001;p. 2964–2976
  4. Shepherd GM. Hypersensitivity reactions to drugs: evaluation and management. Mount Sinai J Med. 2003;70:113–125
  5. Gobel BG. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum. 2005;32:1027–1035
  6. Ream M, Tunison D. Hypersensitivity reactions. In:  Yasko JM editors. Nursing management of symptoms associated with chemotherapy. Ed 5. Bala Cynwyd, PA: Meniscus Limited; 2001;p. 271–282
  7. Thomas M. Treatment-related hypersensitivity reactions to antineoplastic agents (recognition, prevention, and management [Continuing education monograph and self-test]). Skillman, NJ: American Academy of Continuing Medical Education; 2004;
  8. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224
  9. Ditto AM. Drug allergy, part A: Introduction, epidemiology, classification of adverse reactions, immunochemical basis, risk factors, evaluation of patients with suspected drug allergy, patient management considerations. In:  Grammer LC,  Greenberger PA editor. Patterson’s allergic diseases. Ed 6. Philadelphia, PA: Lippincott Williams and Wilkins; 2002;p. 295–334
  10. Barranco P, Lopez-Serrano MC. General and epidemiological aspects of allergic drug reactions. Clin Exp Allergy. 1998;28(suppl 4):61–62
  11. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr. 1992;5:1237–1257
  12. Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137:301–304
  13. Lang DM, Alpern MB, Visintainer PF, et al. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. 1991;115:270–276
  14. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematous: a case-control study. J Rheumatol. 1992;19:265–269
  15. Adkinson NF. Risk factors for drug allergy. J Allergy Clin Immunol. 1984;74:567–572
  16. Cheng JD, Rieger PT, von Mehren M, et al. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs. 2000;16(suppl 1):2–12
  17. Rieger PT, Green M, Murray L. Monoclonal antibodies: Applications in solid tumors and other diseases. In:  Rieger PT editors. Biotherapy. Sudbury, MA: Jones and Bartlett; 2001;p. 317–355
  18. National Cancer Institute. Common terminology criteria for adverse events v 3.0. 2003;Available at. http://ctep.cancer.gov/reporting/ctc.html (accessed December 18, 2006).
  19. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety. 2001;24:767–779
  20. Drain KL, Volcheck GW. Preventing and managing drug-induced anaphylaxis. Drug Safety. 2001;24:843–853
  21. Lieberman P, Kemp SF, Oppenheimer J, et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115:S483–S523
  22. Labovich TM. Acute hypersensitivity reactions to chemotherapy. Semin Oncol Nurs. 1999;15:222–231
  23. Yeung S, Escalante CP. Oncologic emergencies. In:  Kufe DW,  Pollock RE,  Weichselbaum RR, et al. editor. Holland-Frei Cancer Medicine. Ed 5. Hamilton, Ontario: BC Decker Inc; 2000;p. 2659–2670
  24. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169–1176
  25. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  26. Monti M, Mancini LL, Ferrari B, et al. Complications of therapy and a diagnostic dilemma case (Case 2. Cutaneous toxicity induced by cetuximab). J Clin Oncol. 2003;21:4651–4653
  27. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  28. Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002;29(suppl 4):37–46
  29. van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa) an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598–601
  30. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology. 2003;17:23–28
  31. Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol. 2004;5:647
  32. In:  Polovich M,  White JM,  Kelleher LO editor. Chemotherapy and biotherapy guidelines and recommendations for practice. Ed 2. Pittsburgh, PA: Oncology Nursing Society; 2005;
  33. In:  Wilkes GM,  Barton-Burke M editor. Oncology nursing drug handbook. Sudbury, MA: Jones and Bartlett; 2005;
  34. In:  Fischer DS,  Knobf MT,  Durivage HJ, et al. editor. The cancer chemotherapy handbook. Ed 6. Philadelphia, PA: Mosby; 2003;
  35. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB (389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma. 2001;1:298–302
  36. Olsen ED, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376–388
  37. Osterborg A, Dyer MJS, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. J Clin Oncol. 1997;15:1567–1574
  38. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2334–2342
  39. Clinical pharmacology (Cetuximab). 2006;Available at. http://cpip.gsm.com (accessed January 5, 2007).
  40. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29(suppl 4):27–36
  41. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254
  42. Clinical pharmacology (Gemtuzumab ozogamicin). 2006;Available at. http://cpip.gsm.com (accessed January 5, 2007).
  43. Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999;5:3281s–3286s
  44. DeNardo G. Treatment of non-Hodgkin’s lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med. 2002;35:202–211
  45. Vectibix (Panitumumab) (Full prescribing information). Thousand Oaks, CA: Amgen Inc; 2007;
  46. Rituxan (Rituximab) (Full prescribing information). South San Francisco, CA: Genentech, Inc; 2002;Revised February 2002.
  47. Maloney DG, McLaughlin P. Rituximab for the treatment of patients with B-cell non-Hodgkin’s lymphoma. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Progress in oncology. Boston, MA: Jones & Bartlett; 2001;p. 204–227
  48. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs. 2003;63:803–843
  49. Kaminski MS, Tuck M, Estes J, et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–3928
  50. Clinical pharmacology (Interferon alfa). 2006;Available at. http://cpip.gsm.com (accessed January 5, 2007).
  51. Clinical pharmacology (Aldesleukin). 2006;Available at. http://cpip.gsm.com (accessed January 5, 2007).
  52. Runge JW, Martinez JC, Caravati EM, et al. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med. 1992;21:237–242
  53. Joint Task Force on Practice Parameters (The diagnosis and management of anaphylaxis: an updated practice parameter). J Allerg Clin Immunol. 2005;3(suppl 2):S438–S524
  54. Brown AF. Therapeutic controversies in the management of acute anaphylaxis. J Acc Emerg Med. 1998;15:89–95

PII: S0749-2081(07)00059-9

doi: 10.1016/j.soncn.2007.05.009

Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 191-200 , August 2007

Article Tools

* Image Usage & Resolution